Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines
Table 1
Demographic and clinical characteristics of patients with different MS phenotypes.
RRMS
SPMS
PPMS
CIS
Gender F/Ma
24/10
10/5
9/7
13/2
Age (years)b
37.6 ± 9.2 (20–51)
49.3 ± 10.0 (32–63)
58.1 ± 8.5 (40–70)
35.6 ± 7.9 (24–51)
BMI (kg/m2)b
24.9 ± 4.0 (19.7–35.4)
26.2 ± 5.0 (15.8–33.3)
24.6 ± 3.4 (19.8–31.5)
25.3 ± 3.2 (21.6–31.2)
Disease duration from first symptoms (years)b
8.2 ± 7.2 (0.7–29.6)
19.8 ± 7.8 (6.3–34.3)
18.9 ± 9.6 (2.4–43.0)
3.0 ± 2.5 (0.5–8.9)
Disease duration from diagnosis (years)b
4.2 ± 4.1 (0.0–13.7)
12.9 ± 9.0 (2.2–32.4)
13.1 ± 8.4 (1.5–27.2)
NA
EDSS at baselineb
1.4 ± 1.5 (0.0–6.0)
5.2 ± 1.6 (2.5–7.5)
4.7 ± 2.2 (1.0–7.0)
0.1 ± 0.3 (0.0–1.0)
EDSS at end of the follow-upb
1.5 ± 1.6 (0.0–6.0)
5.5 ± 1.6 (2.5–8.0)
4.8 ± 2.1 (1.5–7.0)
0.1 ± 0.4 (0.0–1.0)
EDSS worsening during follow-upc
7 (21%)
6 (40%)
4 (25%)
1 (7%)
Prestudy disease activityb,d
1.2 ± 1.4 (0–5)
0.2 ± 0.6 (0–2)
0.0 ± 0.0 (0-0)
0.7 ± 0.6 (0–2)
Number of relapses over the follow-upb
0.6 ± 1.1 (0–5)
0.4 ± 0.7 (0–2)
0.0 ± 0.0 (0-0)
0.1 ± 0.3 (0-1)
Treatment (NT/IFN/CO/MX)a
12/18/3/1
15/0/0/0
16/0/0/0
15/0/0/0
RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS, CIS: clinically isolated syndrome, BMI: body mass index, EDSS: expanded disability status scale, NT: no treatment, IFN: interferon, CO: copaxone, MX: mitoxantrone, and NA: not applicable. Number of patients. Mean ± SD (range). Number of patients (percent). Number of relapses in the 2 years before baseline.